Chorioretinitis Treatment & Management

  • Author: Ayesha Mirza, MD; Chief Editor: Russell W Steele, MD   more...
 
Updated: Jul 22, 2011
 

Medical Care

  • Medical care in chorioretinitis (CR) focuses on the establishment of specific therapies for treatable etiologies and on the stabilization of the patient with chorioretinitis to prevent further loss of vision especially in immunocompromised infants and children.
  • Care for individuals with chorioretinitis is complex and requires thorough consideration of short-term and long-term care and goals to maintain quality of life.
  • Available treatment options for specific causes of chorioretinitis are as follows:
    • Antivirals: Four drugs have been licensed for the systemic treatment of cytomegalovirus (CMV) infection. These include ganciclovir, valganciclovir (oral prodrug of ganciclovir), foscarnet, and cidofovir. Fomivirsen is licensed for intravitreal administration to treat CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Newer drugs such as maribavir, which has the potential to be useful in ganciclovir-resistant strains of CMV, are under clinical investigation.[9, 24]
    • For children with human immunodeficiency virus (HIV) infection, the drug of choice for initial treatment for CMV retinitis is intravenous ganciclovir. Oral valganciclovir is an option primarily for older children who are able to receive the adult dose and tablet formulation of valganciclovir. An alternative to treat CMV disease or for use in ganciclovir-resistant CMV infections in children with HIV is foscarnet. Combination therapy with ganciclovir and foscarnet delays progression of retinitis in certain patients failing monotherapy and can be used as initial therapy among children with sight-threatening disease. Intravenous ganciclovir and foscarnet may also be considered in initial therapy of CMV CNS disease. However, combination therapy is associated with substantial rates of adverse effects.
    • Several agents are used to treat toxoplasmosis. Treatment with antiparasitic drugs is effective for active infections but not for the encysted form. The classic treatment includes triple drug therapy with pyrimethamine (0.5-1 mg/kg/d), sulfadiazine (120-150 mg/kg/d), and prednisone. Concurrent folinic acid helps to minimize bone marrow toxicity produced by the pyrimethamine. High-performance liquid chromatography with ultraviolet and mass spectrometric detection has been developed for monitoring the plasma levels of pyrimethamine and sulfadiazine during treatment using a small amount of plasma (25 mcL). This may be helpful in determining the relationship between plasma concentrations and treatment efficacy.[25]
    • Alternative antibiotic treatments include atovaquone (40 mg/kg/d has been used in adults, no dosage for children), azithromycin (5 mg/kg/d) and trimethoprim-sulfamethoxazole (40 mg/kg/d sulfamethoxazole, 8 mg/kg/d trimethoprim). Adjunctive clindamycin (20 mg/kg/d) is used for coverage against the encysted form. Treatment duration for congenital infection is typically 1 year.
    • Prevention of fetal infection after maternal Toxoplasma seroconversion during pregnancy is attempted with spiramycin administration. A 60% decrease has been reported in the congenital infection rate in patients who received this treatment; however, it does not ameliorate the fate of infants who are infected.
    • Catscratch disease is usually a self-limited disease in immunocompetent patients. B henselae is sensitive to many antibiotics in vitro, but only aminoglycosides have bactericidal activity. In immunocompetent patients, doxycycline at 200 mg/d is usually administered because of its property to cross the blood-brain and blood-ocular barrier. Caution should be used if administered to children because it may cause dental changes. Ciprofloxacin (1.5 g/d), gentamicin (3-5 mg/kg/d), erythromycin (20-50 mg divided into 3 doses; adults, 2 g/d), trimethoprim-sulfamethoxazole (40 mg/kg/d sulfamethoxazole, 8 mg/kg/d trimethoprim) are good alternatives and, like doxycycline, are usually given for 14-28 days. Immunodeficient patients need a more prolonged course of treatment, usually as long as 4 months. Steroids are also indicated for ocular disease.[26, 27]
    • Treatment of chorioretinitis due to fungal infections can be difficult and prolonged. Intravitreous amphotericin B (5-10 mcg) has been used to treat serious fungal chorioretinitis.
      • Candida species infection: Fluconazole (6-12 mg/kg/d) and amphotericin B (0.75-1 mg/kg/d) has been recommended as preferred antifungals for treatment of Candida endophthalmitis. New-generation triazoles (eg, voriconazole, posaconazole, ravuconazole) are changing the conventional approach to fluconazole-resistant Candida strains, as well as the approach to fungal endophthalmitis. Caspofungin is the first echinocandin approved to treat fungal endophthalmitis. Concomitant systemic caspofungin and voriconazole therapy has successfully treated endophthalmitis due to Candida albicans.[28, 29, 30, 31] Experimental intraocular voriconazole (≤ 25 mcg/mL) has been used for azole-resistant Candida infection with some success.
      • Ocular histoplasmosis: Treatment is limited to photocoagulation of neovascular membranes, particularly when the macula is threatened. Antifungal therapy has no role in treatment of this disease because no actively replicating organisms are present. Amphotericin B is used to treat systemic disease (0.75-1 mg/kg/d).[32]
      • Cryptococcus species infection: Amphotericin B (0.75-1 mg/kg/d) is used.
    • Antituberculosis drugs are administered in patients with M tuberculosis (MTB) and include isoniazid (10-30 mg/kg/d), rifampicin (10-20 mg/kg/d), pyrazinamide (30 mg/kg/d), and ethambutol (15 mg/kg/d). Other drugs, such as aminoglycosides and quinolones, may be used for treatment of drug-resistant organisms. Duration of therapy depends on the extent of the disease and on the immune status of the host.
    • Anthelmintics, including diethylcarbamazine (6 mg/kg/d), albendazole (400 mg PO bid), and mebendazole (100-200 mg PO bid), are usually administered with corticosteroids in patients with toxocariasis or baylisascariasis.
    • Etiologic treatments may not alter the clinical course of chorioretinitis because the pathologic changes may be due to an inflammatory and/or immunologic response instead of infection.
    • Treatment of other infectious etiologies, such as syphilis, yersiniosis, neuroborreliosis, depends on extent of disease but is likely to be successful in most patients.
  • Eye symptoms can be treated as follows:
    • Steroids may have a role in the acute management of many vasculitides, collagen vascular diseases, or sarcoidosis; in some infectious processes (eg, MTB); or in some cases infections caused by Toxoplasma species.
    • Laser treatment of retinal lesions is used in certain conditions with good results.
Next

Surgical Care

  • Vitrectomy is usually not needed and is reserved for severe cases that are resistant to conservative medical treatment.
  • Ocular cytology used to detect the presence of eosinophils, ocular antibody, and immunoglobulin E (IgE) levels should always be performed to differentiate toxocaral ocular larva migrans from malignant retinoblastoma to prevent unnecessary enucleations.
Previous
Next

Consultations

  • Involvement of the following specialists is helpful in performing a diagnostic workup, determining the length of treatment, and planning the total management of a child with chorioretinitis:
    • Ophthalmologist - For determination of eye damage, treatment, and long-term follow-up care
    • Infectious disease specialist - For diagnostic workup, selection of therapeutic agents and options, investigation of potential drug toxicities, and determination of treatment length in consultation with the ophthalmologist
  • Other specialists include the following:
    • Neurologist - For seizure control and long-term follow-up care of neurologic deficits
    • Allergy and immunology/rheumatology specialist - To treat other associated conditions (ie, juvenile rheumatoid arthritis)
    • Audiologist - For assessment and corrective measures to detect and treat deafness (if possible)
    • Physical therapist - For maximization of functions and range of motions of muscles and joints and for referral to an orthopedist for surgical intervention if needed
  • Occasionally, genetic testing is required to investigate possible dysmorphic syndromes.
Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Ayesha Mirza, MD  Assistant Professor, Pediatric Infectious Diseases, University of Florida College of Medicine Jacksonville

Ayesha Mirza, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Tropical Medicine and Hygiene, HIV Medicine Association of America, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Coauthor(s)

Diana E Guinazu, MD  Fellow in Pediatric Infectious Diseases, University of Florida College of Medicine

Diana E Guinazu, MD is a member of the following medical societies: American Academy of Pediatrics and American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Itzhak Brook, MD, MSc  Professor, Department of Pediatrics, Georgetown University School of Medicine

Itzhak Brook, MD, MSc is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, Armed Forces Infectious Diseases Society, Association of Military Surgeons of the US, Infectious Diseases Society of America, International Immunocompromised Host Society, International Society for Infectious Diseases, Medical Society of the District of Columbia, New York Academy of Sciences, Pediatric Infectious Diseases Society, Society for Ear, Nose and Throat Advances in Children, Society for Experimental Biology and Medicine, Society for Pediatric Research, Southern Medical Association, and Surgical Infection Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Mark R Schleiss, MD  American Legion Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota Medical School

Mark R Schleiss, MD is a member of the following medical societies: American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Robert W Tolan Jr, MD  Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Sanofi Pasteur Honoraria Speaking and teaching; Baxter Healthcare Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Quoc V Nguyen, MD, to the original writing and development of this article.

References

  1. Koevary SB. Ocular involvement in patients infected by the West Nile virus. Optometry. Oct 2005;76(10):609-12. [Medline].

  2. Zinkernagel MS, Bolinger B, Krebs P, Onder L, Miller S, Ludewig B. Immunopathological basis of lymphocytic choriomeningitis virus-induced chorioretinitis and keratitis. J Virol. Jan 2009;83(1):159-66. [Medline].

  3. Stagno S, Britt W, et al. Cytomegalovirus Infections. In: Remington J, Klein J, Wilson C, eds. Infectious Diseases of the Fetus and Newborn Infant. 6th ed. Philadelphia, PA: Elsevier; 2006:739-81.

  4. Hall BR, Oliver GE, Wilkinson M. A presentation of longstanding toxoplasmosis chorioretinitis. Optometry. Jan 2009;80(1):23-8. [Medline].

  5. Wise ME, Sorvillo FJ, Shafir SC, Ash LR, Berlin OG. Severe and fatal central nervous system disease in humans caused by Baylisascaris procyonis, the common roundworm of raccoons: a review of current literature. Microbes Infect. Feb 2005;7(2):317-23. [Medline].

  6. Egli A, Bergamin O, Mullhaupt B, et al. Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review of the literature. Transpl Infect Dis. Feb 2008;10(1):27-43. [Medline].

  7. Khairallah M, Chee SP, Rathinam SR, Attia S, Nadella V. Novel infectious agents causing uveitis. Int Ophthalmol. Oct 2010;30(5):465-83. [Medline].

  8. Greydanus DE, Noble KG, Hofmann AD. Chorioretinitis in the adolescent: two case presentations with discussion. Pediatrics. Dec 1977;60(6):884-92. [Medline].

  9. Nassetta L, Kimberlin D, Whitley R. Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J Antimicrob Chemother. May 2009;63(5):862-7. [Medline].

  10. Lopez A, Dietz VJ, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. MMWR Recomm Rep. Mar 31 2000;49:59-68. [Medline].

  11. Elsheikha HM. Congenital toxoplasmosis: priorities for further health promotion action. Public Health. Apr 2008;122(4):335-53. [Medline].

  12. Rothova A. Ocular manifestations of toxoplasmosis. Curr Opin Ophthalmol. Dec 2003;14(6):384-8. [Medline].

  13. Freeman K, Tan HK, Prusa A, et al. Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. Pediatrics. May 2008;121(5):e1215-22. [Medline].

  14. Toxocariasis. CDC; accessed July 17, 2009. [Full Text].

  15. Woods CR. Congenital syphilis-persisting pestilence. Pediatr Infect Dis J. Jun 2009;28(6):536-7. [Medline].

  16. [Guideline] New York State Department of Health. Ophthalmologic complications of HIV infection. New York (NY): New York State Department of Health; 2004 Jan.

  17. Reed JB, Scales DK, Wong MT, Lattuada CP Jr, Dolan MJ, Schwab IR. Bartonella henselae neuroretinitis in cat scratch disease. Diagnosis, management, and sequelae. Ophthalmology. Mar 1998;105(3):459-66. [Medline].

  18. Mikkila H, Seppala I, Leirisalo-Repo M, Immonen I, Karma A. The etiology of uveitis: the role of infections with special reference to Lyme borreliosis. Acta Ophthalmol Scand. Dec 1997;75(6):716-9. [Medline].

  19. Babu RB, Sudharshan S, Kumarasamy N, Therese L, Biswas J. Ocular tuberculosis in acquired immunodeficiency syndrome. Am J Ophthalmol. Sep 2006;142(3):413-8. [Medline].

  20. Andreola C, Ribeiro MP, de Carli CR, Gouvea AL, Curi AL. Multifocal choroiditis in disseminated Cryptococcus neoformans infection. Am J Ophthalmol. Aug 2006;142(2):346-8. [Medline].

  21. Ament CS, Young LH. Ocular manifestations of helminthic infections: onchocersiasis, cysticercosis, toxocariasis, and diffuse unilateral subacute neuroretinitis. Int Ophthalmol Clin. Spring 2006;46(2):1-10. [Medline].

  22. Chalumeau M, Monnet D, Brezin AP, et al. Chorioretinal lesions as the unique feature of complete chronic granulomatous disease in an 8-year-old girl. Eur J Pediatr. Oct 2007;166(10):1069-70. [Medline].

  23. Rigante D, Stabile A, Minnella A, et al. Post-inflammatory retinal dystrophy in CINCA syndrome. Rheumatol Int. May 8 2009;[Medline].

  24. Weiss HA. Uveitis and Chrorioretinitis. In: Long S, ed. Principles and Practice of Pediatric Infectious Diseases. 3rd ed Edition. 2008:504-8.

  25. Johannessen JK, Christiansen I, Schmidt DR, Petersen E, Hansen SH. Simultaneous determination of pyrimethamine, sulfadiazine and N-acetyl-sulfadiazine in plasma for monitoring infants in treatment of congenital toxoplasmosis. J Pharm Biomed Anal. Jan 4 2005;36(5):1093-8. [Medline].

  26. Accorinti M. Ocular bartonellosis. Int J Med Sci. 2009;6(3):131-2. [Medline].

  27. Patel SJ, Petrarca R, Shah SM, et al. Atypical Bartonella hensalae chorioretinitis in an immunocompromised patient. Ocul Immunol Inflamm. Jan-Feb 2008;16(1):45-9. [Medline].

  28. Shah CP, McKey J, Spirn MJ, Maguire J. Ocular candidiasis: a review. Br J Ophthalmol. Apr 2008;92(4):466-8. [Medline].

  29. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol. Jan 2005;139(1):135-40. [Medline].

  30. Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy. Dec 2007;27(12):1711-21. [Medline].

  31. Osthoff M, Hilge R, Schulze-Dobold C, Bogner JR. Endogenous endophthalmitis with azole-resistant Candida albicans--Case report and review of the literature. Infection. Oct 2006;34(5):285-8. [Medline].

  32. Prasad AG, Van Gelder RN. Presumed ocular histoplasmosis syndrome. Curr Opin Ophthalmol. Dec 2005;16(6):364-8. [Medline].

  33. Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics. Jun 2004;113(6):1567-72. [Medline].

 
Previous
Next
 
Chorioretinitis in a patients with acquired immunodeficiency syndrome (AIDS).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.